1. MAGE-A4 and MAGE-A1 Immunohistochemical Expression in High-grade Endometrial Cancer.
- Author
-
Srdelić S, Kuzmić-Prusac I, Spagnoli GC, Juretić A, and Čapkun V
- Subjects
- Adenocarcinoma, Clear Cell metabolism, Adenocarcinoma, Clear Cell mortality, Antibodies, Monoclonal, Carcinoma, Endometrioid metabolism, Carcinoma, Endometrioid mortality, Endometrial Neoplasms metabolism, Endometrial Neoplasms mortality, Endometrium pathology, Female, Humans, Immunohistochemistry, Lymphatic Metastasis, Neoplasm Grading, Retrospective Studies, Survival Analysis, Adenocarcinoma, Clear Cell pathology, Antigens, Neoplasm metabolism, Carcinoma, Endometrioid pathology, Endometrial Neoplasms pathology, Neoplasm Proteins metabolism, Peptide Fragments metabolism
- Abstract
The aim was to investigate MAGE-A4 and MAGE-A1 protein expression in high-grade endometrial cancer and determine its correlation with histologic subtype, FIGO stage, presence of vascular invasion, disease free, and overall survival. Immunohistochemical staining was performed by using 77B (MAGE-A1) and 57B (MAGE-A4) monoclonal antibodies on paraffin-embedded sections from high-grade endometrial cancers diagnosed in University Hospital Split between 1998 and 2011 (n=77). Median follow-up time for survivors was 48 mo. MAGE-A4 was found to be expressed in 33% of endometrioid type endometrial cancers grade 3 and in 27% of serous and clear cell carcinomas. MAGE-A1 was found to be expressed in 93% endometrioid endometrial cancer grade 3 and 86% of serous and clear cell carcinomas. Univariate analysis showed that positive immunohistochemical staining for MAGE-A4 was associated with decreased disease free and overall survival in patients with high-grade endometrial cancer. Multivariate analysis showed an association between MAGE-A4 overexpression and decreased disease free but not overall survival in high-grade endometrial cancer. No correlation was found between MAGE-A1 immunohistochemical expression and patient survival. There was no significant correlation between MAGE-A4 and MAGE-A1 expression and histologic subtype, FIGO stage, lymph node metastasis, muscular infiltration, and lymphovascular invasion. MAGE-A4 immunohistochemical expression is associated with decreased disease free and overall survival in patients with high-grade endometrial cancer. Our findings suggest that MAGE-A1 may be expressed in the epithelial cells of the normal endometrium. MAGE-A1 is highly expressed in high-grade endometrial cancer, with no impact on survival.
- Published
- 2019
- Full Text
- View/download PDF